492 related articles for article (PubMed ID: 18175003)
1. Synthesis and anticancer activity of geldanamycin derivatives derived from biosynthetically generated metabolites.
Lee K; Ryu JS; Jin Y; Kim W; Kaur N; Chung SJ; Jeon YJ; Park JT; Bang JS; Lee HS; Kim TY; Lee JJ; Hong YS
Org Biomol Chem; 2008 Jan; 6(2):340-8. PubMed ID: 18175003
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90.
Ge J; Normant E; Porter JR; Ali JA; Dembski MS; Gao Y; Georges AT; Grenier L; Pak RH; Patterson J; Sydor JR; Tibbitts TT; Tong JK; Adams J; Palombella VJ
J Med Chem; 2006 Jul; 49(15):4606-15. PubMed ID: 16854066
[TBL] [Abstract][Full Text] [Related]
3. Potent cytotoxic C-11 modified geldanamycin analogues.
Tian ZQ; Wang Z; MacMillan KS; Zhou Y; Carreras CW; Mueller T; Myles DC; Liu Y
J Med Chem; 2009 May; 52(10):3265-73. PubMed ID: 19405528
[TBL] [Abstract][Full Text] [Related]
4. Molecular characterization of macbecin as an Hsp90 inhibitor.
Martin CJ; Gaisser S; Challis IR; Carletti I; Wilkinson B; Gregory M; Prodromou C; Roe SM; Pearl LH; Boyd SM; Zhang MQ
J Med Chem; 2008 May; 51(9):2853-7. PubMed ID: 18357975
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and biological evaluation of 17-arylmethylamine-17-demethoxygeldanamycin derivatives as potent Hsp90 inhibitors.
Li Z; Jia L; Wang J; Wu X; Hao H; Xu H; Wu Y; Shi G; Lu C; Shen Y
Eur J Med Chem; 2014 Oct; 85():359-70. PubMed ID: 25105924
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological evaluation of a new class of geldanamycin derivatives as potent inhibitors of Hsp90.
Le Brazidec JY; Kamal A; Busch D; Thao L; Zhang L; Timony G; Grecko R; Trent K; Lough R; Salazar T; Khan S; Burrows F; Boehm MF
J Med Chem; 2004 Jul; 47(15):3865-73. PubMed ID: 15239664
[TBL] [Abstract][Full Text] [Related]
7. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90.
Sydor JR; Normant E; Pien CS; Porter JR; Ge J; Grenier L; Pak RH; Ali JA; Dembski MS; Hudak J; Patterson J; Penders C; Pink M; Read MA; Sang J; Woodward C; Zhang Y; Grayzel DS; Wright J; Barrett JA; Palombella VJ; Adams J; Tong JK
Proc Natl Acad Sci U S A; 2006 Nov; 103(46):17408-13. PubMed ID: 17090671
[TBL] [Abstract][Full Text] [Related]
8. Synthetic ansamycins prepared by a ring-expanding Claisen rearrangement. Synthesis and biological evaluation of ring and conformational analogues of the Hsp90 molecular chaperone inhibitor geldanamycin.
McErlean CS; Proisy N; Davis CJ; Boland NA; Sharp SY; Boxall K; Slawin AM; Workman P; Moody CJ
Org Biomol Chem; 2007 Feb; 5(3):531-46. PubMed ID: 17252137
[TBL] [Abstract][Full Text] [Related]
9. Discovery of novel 17-phenylethylaminegeldanamycin derivatives as potent Hsp90 inhibitors.
Li Z; Jia L; Wang J; Wu X; Shi G; Lu C; Shen Y
Chem Biol Drug Des; 2015 Feb; 85(2):181-8. PubMed ID: 24903735
[TBL] [Abstract][Full Text] [Related]
10. Discovery of diamine-linked 17-aroylamido-17-demethoxygeldanamycins as potent Hsp90 inhibitors.
Li Z; Jia L; Wang J; Wu X; Hao H; Wu Y; Xu H; Wang Z; Shi G; Lu C; Shen Y
Eur J Med Chem; 2014 Nov; 87():346-63. PubMed ID: 25277067
[TBL] [Abstract][Full Text] [Related]
11. Heat shock protein 90: inhibitors in clinical trials.
Biamonte MA; Van de Water R; Arndt JW; Scannevin RH; Perret D; Lee WC
J Med Chem; 2010 Jan; 53(1):3-17. PubMed ID: 20055425
[No Abstract] [Full Text] [Related]
12. New non-quinone geldanamycin analogs from genetically engineered Streptomyces hygroscopicus.
Wu CZ; Moon AN; Jang JH; Lee D; Kang SY; Park JT; Ahn JS; Hwang BY; Kim YH; Lee HS; Hong YS
J Antibiot (Tokyo); 2011 Jun; 64(6):461-3. PubMed ID: 21448187
[No Abstract] [Full Text] [Related]
13. Macrocyclic lactams as potent Hsp90 inhibitors with excellent tumor exposure and extended biomarker activity.
Zapf CW; Bloom JD; McBean JL; Dushin RG; Nittoli T; Otteng M; Ingalls C; Golas JM; Liu H; Lucas J; Boschelli F; Hu Y; Vogan E; Levin JI
Bioorg Med Chem Lett; 2011 Jun; 21(11):3411-6. PubMed ID: 21515049
[TBL] [Abstract][Full Text] [Related]
14. Conformational significance of EH21A1-A4, phenolic derivatives of geldanamycin, for Hsp90 inhibitory activity.
Onodera H; Kaneko M; Takahashi Y; Uochi Y; Funahashi J; Nakashima T; Soga S; Suzuki M; Ikeda S; Yamashita Y; Rahayu ES; Kanda Y; Ichimura M
Bioorg Med Chem Lett; 2008 Mar; 18(5):1588-91. PubMed ID: 18243703
[TBL] [Abstract][Full Text] [Related]
15. Rational biosynthetic engineering for optimization of geldanamycin analogues.
Kim W; Lee D; Hong SS; Na Z; Shin JC; Roh SH; Wu CZ; Choi O; Lee K; Shen YM; Paik SG; Lee JJ; Hong YS
Chembiochem; 2009 May; 10(7):1243-51. PubMed ID: 19308924
[TBL] [Abstract][Full Text] [Related]
16. The interplay between mutasynthesis and semisynthesis: generation and evaluation of an ansamitocin library.
Eichner S; Knobloch T; Floss HG; Fohrer J; Harmrolfs K; Hermane J; Schulz A; Sasse F; Spiteller P; Taft F; Kirschning A
Angew Chem Int Ed Engl; 2012 Jan; 51(3):752-7. PubMed ID: 22135226
[No Abstract] [Full Text] [Related]
17. Expression of epidermal growth factor receptor or ErbB3 facilitates geldanamycin-induced down-regulation of ErbB2.
Pedersen NM; Breen K; Rødland MS; Haslekås C; Stang E; Madshus IH
Mol Cancer Res; 2009 Feb; 7(2):275-84. PubMed ID: 19208749
[TBL] [Abstract][Full Text] [Related]
18. Engineered biosynthesis of geldanamycin analogs for Hsp90 inhibition.
Patel K; Piagentini M; Rascher A; Tian ZQ; Buchanan GO; Regentin R; Hu Z; Hutchinson CR; McDaniel R
Chem Biol; 2004 Dec; 11(12):1625-33. PubMed ID: 15610846
[TBL] [Abstract][Full Text] [Related]
19. Rational design and synthesis of ansa-adenosines as potential antitumor agents.
Muranaka K; Ichikawa S; Matsuda A
Nucleic Acids Symp Ser (Oxf); 2009; (53):5-6. PubMed ID: 19749232
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological evaluation of geldanamycin analogs against human cancer cells.
Li YP; Chen JJ; Shen JJ; Cui J; Wu LZ; Wang Z; Li ZR
Cancer Chemother Pharmacol; 2015 Apr; 75(4):773-82. PubMed ID: 25681003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]